What we're reading, January 25, 2016: Cigna faces sanctions from CMS; a Massachusetts senator blocks the nomination of Robert Califf, MD, for FDA commissioner; and hospitals and health systems are mostly unprepared for precision medicine.
CMS is imposing sanctions on Cigna as a result of a number of issues, including a “longstanding history of noncompliance.” The government halted enrollment into Cigna’s Medicare Advantage and prescription drug plans and has blocked the insurer from marketing its Medicare plans, according to The Wall Street Journal. The timing of the penalty comes after the annual Medicare open enrollment period, which will limit the impact, and despite the sanctions, Anthem stated it remains committed to its $48 billion acquisition of Cigna.
The nominee for FDA commissioner may have overcome his first hurdle by being approved unanimously by a Senate panel committee, but a US senator is blocking the nomination over opiate approvals. The Boston Globe reported that Edward Markey, a Massachusetts Democrat, is blocking Robert Califf, MD, in an attempt to get the FDA to rescind approval of prescribing opioids for children. Markey has made the growing opioid epidemic a legislative priority and also wants the agency to change its regulatory practices.
A survey of hospital and health systems has found that organizations are mostly unprepared for precision medicine despite the fact that the White House announced a $215 million precision medicine initiative a year ago. Responses are split, however, with academic medical centers largely believing precision medicine will play a significant role over the next 5 years, but the majority of all respondents said it would not, reported Healthcare Informatics. Nearly two-thirds of respondents said they had no plans to integrate genomic data into their electronic health records, but half believe DNA sequencing could have a positive impact on patient treatment strategies.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More